ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Hoai Thu Dao1,5, Woo-Sung Shin2, Van Tan Do1,5, Quang Lam Truong3, Jong-Young Choi1,4 and Tae-Wook Hahn1,2
1College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 24341, Korea.
2Innovac Co., Kangwon National University, 1 Kangwondaehak-gil, Chuncheon 24341, Korea.
3Key Laboratory of Veterinary Biotechnology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi, Vietnam.
4Dodam Veterinary Clinics, Seoul 04716, Korea.
5Institute of Veterinary Research and Development of Central Vietnam, Vietnam.
J Pure Appl Microbiol. 2021;15(1):164-174 | Article Number: 6438
https://doi.org/10.22207/JPAM.15.1.11 | © The Author(s). 2021
Received: 29/05/2020 | Accepted: 04/01/2021 | Published: 02/02/2021
Abstract

Actinobacillus pleuropneumoniae (App) and Mycoplasma hyopneumoniae (Mhp) cause porcine pleuropneumonia and mycoplasmal pneumonia, respectively, and have serious impacts on the swine industry because they retard the growth of pigs. To protect pigs against these diseases, we have developed a multivalent vaccine consisting of App bacterins, APP RTX toxins (Apx toxins), and Mhp bacterin and adhesin protein. This vaccine induced the production of higher levels of antibodies against App and Mhp than the commercial vaccine (Nisseiken Swine APM Inactivated Vaccine). Furthermore, the vaccine efficiently protected pigs against virulent App challenge, showing promise as an efficient vaccine for the prevention of two important respiratory diseases, porcine pleuropneumonia and mycoplasmal pneumonia.

Keywords

Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, multivalent vaccine, immune responses, protection efficacy

Article Metrics

Article View: 47

Share This Article

© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.